Creation of a macrolide antibiotic against non-tuberculous Mycobacterium using late-stage boron-mediated aglycon delivery
Science Advances · 2025
DOI: 10.1126/sciadv.adt2352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Yuka Isozaki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 3-14-1 Hiyoshi, Kohoku-ku, Yokohama 223-8522, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Boron, Macrolides, Nontuberculous Mycobacteria. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Non-tuberculous mycobacteria (NTM) is gaining clinical recognition as a recently emerging pulmonary pathogen. Mycobacterium avium complex (MAC), the most common NTM, is the cause of pulmonary MAC disease. Currently, the macrolide azithromycin (AZM) is the standard first-line antibiotic for treatment of the disease. However, the rise of drug-resistant MAC necessitates the development of alternative therapeutics. Here, we present a late-stage boron-mediated aglycon delivery strategy for selective modification of AZM, generating a library of potential anti-MAC drugs designated KU01 to KU13 . Screening of KU01 to KU13 revealed that KU13 exhibited enhanced antimicrobial activity against wild-type and macrolide-resistant MAC compared to AZM. Cryo–electron microscopy analysis indicated that the inserted tercyclic moiety of KU13 formed a robust anchor on the bacterial ribosome, creating a binding pocket with base flipping of U2847, potentially bypassing the standard mechanism of macrolide resistance. These results position KU13 as a promising lead for therapeutics against macrolide-resistant MAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 3-14-1 Hiyoshi, Kohoku-ku, Yokohama 223-8522, Japan.
- Graduate School of Life Sciences, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, Miyagi 980-8577, Japan.
- The Advanced Center for Innovations in Next-Generation Medicine (INGEM), Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8573, Japan.
- Institute of Microbial Chemistry (BIKAKEN), 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan.
ORCID-Profile: Yuka Isozaki, Daiki Nishihara, Maho Fujino, Masayuki Igarashi, Takeshi Yokoyama, Kazunobu Toshima, Daisuke Takahashi
Zitieren
APA
Isozaki, Y., Makikawa, T., Kimura, K., Nishihara, D., Fujino, M., Tanaka, Y., Hayashi, C., Ishizaki, Y., Igarashi, M., Yokoyama, T., Toshima, K., & Takahashi, D. (2025). Creation of a macrolide antibiotic against non-tuberculous Mycobacterium using late-stage boron-mediated aglycon delivery. Science Advances. https://doi.org/10.1126/sciadv.adt2352
Vancouver
Isozaki Y, Makikawa T, Kimura K, Nishihara D, Fujino M, Tanaka Y, et al. Creation of a macrolide antibiotic against non-tuberculous Mycobacterium using late-stage boron-mediated aglycon delivery. Science Advances. 2025. doi:10.1126/sciadv.adt2352
BibTeX
@article{Isozaki2025,
author = {Isozaki, Yuka and Makikawa, Takumi and Kimura, Kosuke and Nishihara, Daiki and Fujino, Maho and Tanaka, Yoshikazu and Hayashi, Chigusa and Ishizaki, Yoshimasa and Igarashi, Masayuki and Yokoyama, Takeshi and Toshima, Kazunobu and Takahashi, Daisuke},
title = {Creation of a macrolide antibiotic against non-tuberculous Mycobacterium using late-stage boron-mediated aglycon delivery},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adt2352}
}
EUVIMED